<h1>Pharma Company Reports 19.1% Q1 EBITDA Growth, 1,000 Approvals, and New EU Contract Revenue</h1> A pharmaceutical manufacturing company reported a 19.1% year-on-year growth in adjusted EBITDA for Q1 FY26, achieving total income of Rs. 1,051 crore and improved margins. The company reached 1,000 regulatory approvals from the national drug authority, including 27 new approvals this quarter, and secured a patent for an extended-release drug formulation. It received its first European Union dossier approval and filed a dossier in Switzerland, with commercial supplies for the EU contract expected to begin in April 2027. The company also received 100 million Euros as part of the EU contract consideration, resulting in a strong cash surplus. While some business segments remain in operational loss, efforts to reduce losses continue. The company emphasized its focus on global expansion, research and development, and sustainable growth despite industry challenges such as declining active pharmaceutical ingredient prices.